Plain-English translation of NCT05428488 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Rheumatoid arthritis happens when your immune system attacks your joints, causing pain and damage. This trial tests a new treatment plan using two different medications in sequence. First, you'll take a TNF inhibitor (a type of biologic) for 12 weeks to calm inflammation quickly, then if you're responding well, you'll switch to abatacept, another biologic that works differently and may help prevent the disease from coming back.
Doctors usually keep patients on the first biologic medication even if it's working partially, because they worry about side effects or think other treatments might work better. This study asks whether switching to abatacept—a medication that works on a different part of the immune system and may have fewer side effects—could be even more effective after the inflammation is under control.
You likely qualify if…
You likely don't qualify if…
You'll start by taking TNF inhibitor injections under your skin for 12 weeks. At week 12, your doctor will check how well the medication is working. If you're responding well enough, you'll be randomly assigned to either continue the TNF inhibitor or switch to abatacept for the next 36 weeks. Throughout the 48-week study, you'll have regular clinic visits to monitor your joint inflammation, side effects, and how well the treatment is working.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
France